3rd Feb 2016 07:07
LONDON (Alliance News) - Drugmaker AstraZeneca PLC on Wednesday said it has secured conditional marketing approval from the European Commission For Tagrisso, or osimertinib, tablets used in the treatment of lung cancer.
Eligibility for using the Tagrisso treatment will be dependent on the mutation status of a patients' cancer, which will be validated using a diagnostic test or based on a tumour tissue sample or plasma.
"Osimertinib defines a new generation of targeted EGFR-TKI treatments, and the European Commission's expedited approval reflects the importance of this innovative medicine for addressing the needs of patients with lung cancer who have the T790M mutation," said Sean Bohen, executive vice-president of global medicines development and chief medical officer at AstraZeneca.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca